Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance)
Fadelu T, Zhang S, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson AB, Atienza DM, Messino M, Kindler HL, Venook A, Ogino S, Ng K, Wu K, Willett W, Giovannucci E, Meyerhardt J, Bao Y, Fuchs CS
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 49 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Cohort study (indexed by PubMed)
- Studied in
- People
- Main outcome
- Clinical events such as disease or death
- Intake measured by
- Food frequency questionnaire
Who paid for it
- Funding
- Independent funding
- Government
- National Cancer Institute
- Government
- National Institute of Diabetes and Digestive and Kidney Diseases
- Government
- NCI NIH HHS
- Government
- NIDDK NIH HHS
- Grants
- National Cancer Institute (R01CA149222); National Cancer Institute (K07CA148894); National Cancer Institute (R01CA118553); National Institute of Diabetes and Digestive and Kidney Diseases (P30DK046200); National Cancer Institute (U10 CA180821); National Cancer Institute (U10-CA180888); National Cancer Institute (U10CA180836); National Cancer Institute (U10 CA180867); National Cancer Institute (U10 CA180791); National Cancer Institute (R01CA169141); National Cancer Institute (R35CA197735); National Cancer Institute (R01 CA205406); National Cancer Institute (U10CA180820); National Cancer Institute (U10-CA180882); National Cancer Institute (U10 CA138561); National Cancer Institute (P50-CA127003); National Cancer Institute (UG1 CA189974); National Cancer Institute (UG1CA189858); National Cancer Institute (#P30-CA008748)
Based on 4 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2018-02-28 · J Clin Oncol · vol. 36 · issue 11 · pp. 1112–1120
- Publisher
- Lippincott Williams & Wilkins
- Cited
- 66 citations · more than 97% of similar papers · 5.1× the field average
- Impact
- Top 10% most cited in its field
- References
- 87 works
- Access
- Open access (hybrid journal) · CC-BY-NC-ND
- Research areas
- Nuts composition and effects · Tea Polyphenols and Effects · Nutritional Studies and Diet
- Keywords
- Medicine, Hazard ratio, Internal medicine, Colorectal cancer, Glycemic load, Proportional hazards model, Cancer, Type 2 diabetes, Observational study, Prospective cohort study, Diabetes mellitus, Surgery, Glycemic index, Gastroenterology, Glycemic, Confidence interval, Insulin, Endocrinology
- MeSH
- humans, nuts, colonic neoplasms, neoplasm recurrence, local, antineoplastic combined chemotherapy protocols, neoplasm staging, treatment outcome, chemotherapy, adjuvant, diet, incidence, risk factors, prospective studies, nutritive value, time factors, aged, middle aged, diet records, female, male, randomized controlled trials as topic, protective factors
22 authors
- Temidayo A. Fadelu
- Sui Zhang
- Donna Niedzwiecki
- Xing Ye
- Leonard B. Saltz
- Robert J. Mayer
Abstract
Purpose Observational studies have reported increased colon cancer recurrence and mortality in patients with states of hyperinsulinemia, including type 2 diabetes, obesity, sedentary lifestyle, and high glycemic load diet. Nut intake has been associated with a lower risk of type 2 diabetes, metabolic syndrome, and insulin resistance. However, the effect of nut intake on colon cancer recurrence and survival is not known. Patients and Methods We conducted a prospective, observational study of 826 eligible patients with stage III colon cancer who reported dietary intake on food frequency questionnaires while enrolled onto a randomized adjuvant chemotherapy trial. Using Cox proportional hazards regression, we assessed associations of nut intake with cancer recurrence and mortality. Results After a median follow-up of 6.5 years, compared with patients who abstained from nuts, individuals who consumed two or more servings of nuts per week experienced an adjusted hazard ratio (HR) for disease-free survival of 0.58 (95% CI, 0.37 to 0.92; Ptrend = .03) and an HR for overall survival of 0.43 (95% CI, 0.25 to 0.74; Ptrend = .01). In subgroup analysis, the apparent benefit was confined to tree nut intake (HR for disease-free survival, 0.54; 95% CI, 0.34 to 0.85; Ptrend = .04; and HR for overall survival, 0.47; 95% CI, 0.27 to 0.82; Ptrend = .04). The association of total nut intake with improved outcomes was maintained across other known or suspected risk factors for cancer recurrence and mortality. Conclusion Diets with a higher consumption of nuts may be associated with a significantly reduced incidence of cancer recurrence and death in patients with stage III colon cancer.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-ND).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.